Passaro A - Search Results

1

The impact of chemotherapy on the lymphatic system in thoracic oncology.

Passaro A, Trenta P, Conte D, Campennì G, De Benedetto A, Cortesi E. Passaro A, et al. Thorac Surg Clin. 2012 May;22(2):243-9. doi: 10.1016/j.thorsurg.2011.11.002. Epub 2011 Dec 29. Thorac Surg Clin. 2012. PMID: 22520292 Review.

2

Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?

Passaro A, Cortesi E, de Marinis F. Passaro A, et al. Expert Rev Anticancer Ther. 2011 Oct;11(10):1587-97. doi: 10.1586/era.11.120. Expert Rev Anticancer Ther. 2011. PMID: 21999132 Review.

3

Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer.

Passaro A, Palazzo A, Trenta P, Mancini ML, Morano F, Cortesi E. Passaro A, et al. Curr Med Chem. 2012;19(22):3689-700. doi: 10.2174/092986712801661149. Curr Med Chem. 2012. PMID: 22680928 Review.

4

Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules.

Alesini D, Iacovelli R, Palazzo A, Altavilla A, Risi E, Urbano F, Manai C, Passaro A, Magri V, Cortesi E. Alesini D, et al. Among authors: passaro a. Oncology. 2013;84(2):92-9. doi: 10.1159/000343821. Epub 2012 Nov 2. Oncology. 2013. PMID: 23128186 Review.

5

Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.

Passaro A, Alesini D, Pochesci A, Cortesi E. Passaro A, et al. Anticancer Agents Med Chem. 2014 Jun;14(5):646-50. doi: 10.2174/187152061405140501101624. Anticancer Agents Med Chem. 2014. PMID: 23140355 Review.

6

Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?

Passaro A, Fasano M, Bria E, Morgillo F, Cantile F, Alesini D, Pellegrino A, Cortesi E, Ciardiello F. Passaro A, et al. Lung Cancer. 2013 Jun;80(3):352-3. doi: 10.1016/j.lungcan.2013.01.023. Epub 2013 Feb 26. Lung Cancer. 2013. PMID: 23453130 No abstract available.

7

Neoadjuvant EGFR TKIs: toward personalized management in non-small-cell lung cancer.

Passaro A, Cortesi E. Passaro A, et al. Transl Lung Cancer Res. 2012 Dec;1(4):280-2. doi: 10.3978/j.issn.2218-6751.2012.09.11. Transl Lung Cancer Res. 2012. PMID: 25806194 Free PMC article. No abstract available.

8

Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.

Grossi F, Genova C, Crinò L, Delmonte A, Turci D, Signorelli D, Passaro A, Soto Parra H, Catino A, Landi L, Gelsomino F, Tiseo M, Puppo G, Roila F, Ricciardi S, Tonini G, Cognetti F, Toschi L, Tassinari D, Scoppola A, Giannarelli D, Cortesi E. Grossi F, et al. Among authors: passaro a. Eur J Cancer. 2019 Dec;123:72-80. doi: 10.1016/j.ejca.2019.09.011. Epub 2019 Oct 28. Eur J Cancer. 2019. PMID: 31671314

9

Afatinib in NSCLC harbouring EGFR mutations.

de Marinis F, Catania C, Passaro A. de Marinis F, et al. Among authors: passaro a. Lancet Oncol. 2014 Apr;15(4):e148-9. doi: 10.1016/S1470-2045(13)70402-9. Lancet Oncol. 2014. PMID: 24694632 No abstract available.

10

management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.

Passaro A, Di Maio M, Del Signore E, Gori B, de Marinis F. Passaro A, et al. Clin Lung Cancer. 2014 Jul;15(4):307-12. doi: 10.1016/j.cllc.2014.04.006. Epub 2014 May 12. Clin Lung Cancer. 2014. PMID: 24954231

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

353 results

Search Page

Filters